resiatant malaria final
TRANSCRIPT
![Page 1: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/1.jpg)
PHARMACOTHERAPY & RECENT ADVANCES OF
CHLOROQUINE RESISTANT MALARIA
BY- Dr. NITIN SHINDE•Resident Dept. of Pharmacology
• LOKMANYA TILAK MUNICIPAL MEDICAL COLLEGE & GENERAL HOSPITAL.
•SION, MUMBAI– 400022.• DATE – 12-09-2015. 1
![Page 2: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/2.jpg)
Overview-Pharmacotherapy Introduction with Global & Indian Scenario chloroquine resistant
malaria. Definition of Chloroquine resistant malaria. Mechanism of Chloroquine resistant malaria. Diagnosis of Chloroquine resistant malaria. Pharmacotherapy of uncomplicated P.Falciparum Chloroquine
resistant malaria Pharmacotherapy of complicated Chloroquine resistant malaria Pharmacotherapy of P.Vivax Chloroquine resistant malaria Pharmacotherapy of Chloroquine resistant malaria in pregnancy Guidelines for the management of chloroquine resistant malaria Chemoprophylaxis of chloroquine resistant malaria
2
![Page 3: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/3.jpg)
Overview-Recent Advances
Newer combinations. EXISTING TARGETS- NEW DRUGS. New targets- New Drugs- Fosmidomycin,TES, OZ439. Drugs reversing Chloroquine Resistance New chemosensitizing agents- Tricyclic acridone
molecules. Newer Drug Targets- Apicoplast and others. Antimalarial Vaccine- Pre-erythrocytic, Erythrocytic and
Transmission Blocking Vaccines. Role of genome sequencing. Natural Agents. Conclusion.
3
![Page 4: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/4.jpg)
Introduction:
Malaria kills 1.5 to 2.7 m people world wide every year
95% are due to P.falciparum
In India P. falciparum up to 34%
Case fatality rate is up to 9%
Chloroquine resistance is major concern
Multi drug resistance emerged in India
![Page 5: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/5.jpg)
Global Scenario….P. falciparum resistance Chloroquine resistant strains are found now in
nearly all areas of chloroquine use including South America, Central America, east of the Panama Canal, the Western Pacific, East Asia
P. vivax resistance Recent reports from Indonesia (Irian Jaya, Sumatra)
and Papua, New Guinea Papua, New Guinea indicate high levels of P. vivax schizonts resistant to chloroquine.
P. ovale and P. malariae resistance P. ovale and P. malariae forms have not shown
resistance to chloroquine
5
![Page 6: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/6.jpg)
Indian Scenario… NMCP(1953-58)- Incidance of malaria declined from 75
million cases & 8 Lakh deaths to about 1-2 million cases and zero death till 1958.
NMEP(1963)- More than 120 million cases and 20 Lakh deaths in next two years.
The first confirmed report of chloroquine resistance in P. falciparum was reported in Diphu Diphu area of Karbianglong Karbianglong district of Assam in 1973.district of Assam in 1973.
Incidence being 5% to full dose chloroquine Resurgence of P. falciparum resistant to chloroquine has
been noticed in several regions of India, more in North Eastern parts of the country
NMCP- National Malaria Control ProgrammeNMEP- National Malaria Eradication Programme
6
![Page 7: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/7.jpg)
BURDEN OF DRUG RESISTANTMALARIA
Recurrent infections More malaria –More deaths Epidemics Work/school, productivity, Anaemia, Pregnancy complications Greater financial costs - (Health service,community, individual)
7
![Page 8: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/8.jpg)
DefinitionThe ability of a parasite strain to survive or multiply despite the
administration and absorption of a drug given in doses equal to or higher than those usually recommended but within the
tolerance of the subject (WHO, 1986). provided that the drug gained access to the parasite or the infected red cell for the
duration of time necessary for its action. (Bruce-Chwatt et al,).
Another definition:
It is the ability of a parasite strain to multiply or to survive in the presence of concentrations of a drug that normally destroy parasites of the same species or prevent their
multiplication.
![Page 9: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/9.jpg)
Mechanism Of Resistance Resistant strains are able to
efflux the drug by an active pump mechanism.
pfcrt gene encodes a transporter in the membrane of acidic digestive vacuole causing efflux of chloroquine from the food vacuole
:K76T Mutation There is an increase in the
surface area of the resistant parasites, permitting more efficient pinocytosis.
9
![Page 10: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/10.jpg)
Diagnosis of Chloroquine resistant malaria Clinical Diagnosis Malaria Blood Smear Fluorescent microscopy (RDT)Rapid Diagnostic Tests: Serological test
with PF-HRP-2. It should be noted that Pf HRP-2 based kits may
show positive result up to three weeks after successful treatment and parasite clearance.
In these cases, results should be correlated with microscopic diagnosis.
10
![Page 11: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/11.jpg)
![Page 12: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/12.jpg)
Pharmacotherapy of uncomplicated P.Falciparum Chloroquine resistant malaria with Artemisinine Combination Therapy.
12
![Page 13: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/13.jpg)
What are Artemisinins ?
Artemisinin derivatives
Methyl Ether
Hemisuccinate
Ethyl Ether
Arteether Artemether
Artesunate
Dihydroartemisin
Qinghaosu ("ching-how-soo")
Artesunate Artemether Arteethersolubility Water soluble Lipid soluble Lipid soluble
Route oral, IM, IV oral, IM IM
Metabolite DHA DHA DHA
t1/2 2-4 hrs 3-10 hrs 23 hrs
Side effects
Drug fever,rashCardio toxicity,Raised liver enzymes,
Cardio toxicity,Blood changes,Raised liverEnzymes,Neurotoxicity.
NeurotoxicityNausea,Dizziness,Depressed GIT activity
![Page 14: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/14.jpg)
WHY ACT FOR CHLOROQUINE RESISTANT MALARIA?
• The artemisinins produce rapid clearance of parasitaemia and rapid resolution of symptoms
• Combination therapy prevents resistance.• Shorter T ½ so only problem is Recrudescence.
The partner medicine :• Have different mechanisms of action ,• longer half-lives• and must independently be sufficiently
efficacious in treating malaria.
14
![Page 15: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/15.jpg)
ARTEMISININ BASED COMBINATION THERAPY (ACT)
WHO Recommends following Artemisinin based
combination regimes for the management of
Chloroquine resistant P.Falciparum malaria.
1. Artesunate-sulfadoxine + Pyrimethamine(AS-S/P)
2.Artemether-Lumefantrine(AS/LF)
3.Artesunate/Mefloquine(AS/MQ)
4. Artesunate-Amodiaquine(AS/AQ)
5. Dihydroartemisinin(DHA)-Piperaquine
WHO
NVBDCP
![Page 16: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/16.jpg)
ACT regimen Comment
Artesunate-Sulfadoxine/PyrimethamineAS 100mg BD X 3d + S 1500mg (25mg/kg) + P 75mg (1.25mg/kg) single dose
1st line drug for falciparum under NVBDCP, India. > 96% cure rateNon effective against MDR strain for S/P(north-east India)
Artemether/Lumefantrine (1:6) AM 80mg BD + Lf 480mg BD X 3d (adult dose) >35kg = adult dose, 25-35kg= 3/4th dose, 15-25kg= ½ dose, 5-15kg = 1/4th dose
FDC approved.Preferred in (north-east India).African countries.Lf Given with fatty food, t/2 -- 2-3d, highly effective. 95-99% cure rateBoth can raise QT int. c/i in 1st Trimester of pregnancy and lactation.
Artesunate/Mefloquine
AS -100mg BD (4mg/kg/day) X 3d +MQ -750mg (15mg/kg) on day2 & 500mg (10mg/kg) on day3
FDC approved . Highly effective, well tolerated. Extensive use in Thailand & Myanmar, MQ-Resistance prevented
DHA/ piperaquine (1:8)DHA 120mg (2mg/kg) + piperaquine 960mg (16mg/kg) X 3d
Efficacy comparable to AM/LF, children- well tolerated> 98% cure rate
![Page 17: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/17.jpg)
ACT regimen Comment
Artesunate-AmodiaquineArtesunate 200mg(4 mg/kg/day) + Amodiaquine600mg (10mg/kg) per day X 3days.
Early results encouraging, Low costAQ –short t/2, active metabolite, t/2 = 10-18d.Reduced Agranulocytosis and hepatotoxicity.Recently Approved in India.
Artorolane/piperaquineArtorolane150mg + piperaquine750mg per day X 3days.
Arterolane synthetic analogue, developed in India, low cost & well tolerated.Not FDA Approved.
![Page 18: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/18.jpg)
18
Artesunate + mefloquine VsArtemether + lumefantrine
RCT - A total of 470 (235 in each arm) patients were enrolled
The unadjusted 28-day cure rate was higher in artesunate-mefloquine arm than in the artemether-lumefantrine arm (79.7% versus 67.8%; P < 0.004)
After correction for reinfection, the 28-day cure rates were similar in the two groups (96.04% versus 96.93%)
![Page 19: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/19.jpg)
19
![Page 20: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/20.jpg)
Pharmacotherapy of Chloroquine resistant Severe P.falciparum malaria
20
![Page 21: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/21.jpg)
(Complicated)Severe falciparum malaria
cerebral malaria- Coma, convulsions Renal Impairment Noncardiogenic pulmonary edema Liver Dysfunction Hypoglycemia Metabolic acidosis. Hematological abnormality like hemoglobinuria, Normocytic anemia, bleeding, DIC Other complications : jaundice, extreme weakness,
impaired consciousness. Hypotension/shock
21
![Page 22: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/22.jpg)
Management Of Severe Malaria Rapid clinical assessment and confirmation of the
diagnosis full doses of parenteral antimalarial treatment should be started without delay.
1. Artesunate 2.4 mg/kg i.v. or i.m. given on admission (time = 0), then repeat the dose at 12 h and 24 h, then once a day for 7d.
2. Artemether 3.2 mg/kg i.m. given on admission then 1.6 mg/kg per day for next 7 days.
*Recommended by NVBDCP
![Page 23: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/23.jpg)
3. Arteether 3.2 mg/kg i.m. given on admission then 1.6 mg/kg per day for next 4 days.
Switch to oral 3 day ACT whenever pt can take oral medicines.
![Page 24: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/24.jpg)
QUININE IV INFUSION- (7 days course)
Loading dose : 20mg/kg i.v over 4hrs diluted in 5% dextrose to prevent hypoglycemia Followed by -Maintenance Dose: 10mg/kg over 4hr in adults or 2hr in children every 8hrly till patients condition improves.Then switch over to oral Quinine 600 mg (10mg/kg) TDS to complete the 7 day course.Doxycycline 100 mg OD can also be given with quinine
24
![Page 25: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/25.jpg)
Parental Artemisinin are fast ,more effective, better tolerated and now preferred over Quinine for severe malaria
Adverse effects of Quinine
Higher doses : Affects hearing & vision,Cardio depressant , hemoglobinuria.
QT prolongation during i.v On rapid i.v it causes hypotension. Cinchonism :Reversible Ringing in ears, nausea, vomiting, headache, mental
confusion, vertigo, difficulty in hearing & visual disturbance, diarrhoea ,flushing & marked perspiration .
25
![Page 26: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/26.jpg)
Pharmacotherapy of Chloroquine resistant
P. Vivax malaria
26
![Page 27: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/27.jpg)
CHLOROQUINE RESISTANT P. VIVAX
Recent development.
Gravity of the threat posed by vivax malaria to public health has been poorly appreciated
Resistance in P. vivax is more serious as hypnozoites will cause relapse of resistant parasites.
Reported in focal areas of India, Burma, Indonesia, Papua ,New Guinea, Brazil, Guyana, Colombia and Solomon Islands
27
![Page 28: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/28.jpg)
CHLOROQUINE RESISTANT P. VIVAX
Quinine 600 mg (10 mg/kg every 8 h. with Doxycycline 100 mg once a day are administered for 7 days.
This is followed by Primaquine 15 mg (0.25 mg/kg ) once a day for 14 days.
NVNVBDCP: : 7 day quinine 600mg 8hrly+ Doxycycline 100mg daily/clindamycin 600mg 12hrly is second line treatment in chloroquine resistance to falciparum & vivax malaria plus Primaquine for 30 Days.
28
![Page 29: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/29.jpg)
Treatment of Malaria in Pregnancy• P. falciparum:
• 1st Trimester: Quinine 600mg TDS for 7 days
2nd & 3rd Trimester: ACT– Any ACT combination or– Artesunate + Clindamycin 7 days or– Quinine + Clindamycin 7 days
• P vivax: Clindamycin 10 mg/kg. • Note: Primaquine is contraindicated in
pregnancy.
29
![Page 30: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/30.jpg)
Guidelines for treatment of Malaria -2014
![Page 31: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/31.jpg)
Grading of Resistance:Sensitive (S):Clearance of parasitaemia within 7 days
without recrudescence
Low Grade Resistance (R1): Clearance of parasitaemia followed by recrudescence ( 28 Days after the last dose)
High Grade ( RII): Greater than 75% but less than 100% of parasites cleared within 7 days
High Grade ( RIII) : Parasite count does not fall by more than 75%
31
![Page 32: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/32.jpg)
32
Recommended ACT in national drug policy is fixed dose combination (FDC) of Artemether-lumefantrine (AL).
Not recommended during the first trimester of pregnancy and for children weighing <5 kg.
![Page 33: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/33.jpg)
Lumefantrine(Aminoalcohol)
Tissue Stage
Blood Stage
Gametocidal
Pf
Pv
Po
Pm
As combination, in Treatment of of Multidrug resistant P.f malaria
• Structurally similar to Structurally similar to Mefloquine .Mefloquine .
• Oral BA- variable, better Oral BA- variable, better with fatty foodswith fatty foods
• Elimination t1/2 - 3 daysElimination t1/2 - 3 days
• Well tolerated as Well tolerated as compared to compared to halofantrinehalofantrine
• Nausea, abdominal Nausea, abdominal discomfort, headache discomfort, headache and dizzinessand dizziness
• Prolongation of QT Prolongation of QT interval.(less than interval.(less than halofentrine )halofentrine )
• C/I in Pregnancy and C/I in Pregnancy and lactation.lactation.
![Page 34: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/34.jpg)
Chemoprophylaxis Non immune travellers Army units Migrant workers
![Page 35: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/35.jpg)
Chemoprophylaxis
Short-term chemoprophylaxis (less than 6 weeks) Doxycycline: 100 mg daily in adults 1.5 mg/kg for children> 8 years old The drug should be started 2 days before travel and
continued till 4 weeks after returning from endemic area of chloroquine resistant malaria.
Long-term chemoprophylaxis (more than 6 weeks) Mefloquine: 250 mg or 5 mg/kg started 1-2 weeks
before taken weekly till 4 weeks after return from endemic area.
administered two weeks before, during and four weeks after leaving the area.
36
![Page 36: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/36.jpg)
37
Mefloquine
Spectrum- Blood schizontocide No activity against hepatic stages & gametocytes
Pharmacokinetics Well absorbed orally Parenteral preparations cause severe local reactions Widely distributed Highly bound (~98%) to plasma proteins Terminal t ½ of ~20 days
![Page 37: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/37.jpg)
38
Contd…
Prophylaxis and chemotherapy of drug-resistant P. falciparum and P. vivax malaria
Adverse effects- Nausea, vomiting, dizziness, and neuropsychiatric
reactions
C/I - patients with a history of seizures Should not be given with halofantrine
Approved for pregnancy (after first trimester)
![Page 38: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/38.jpg)
Atovaquone- Proguanil(Malarone)DRUG ADULT DOSE PEDIATRIC
DOSE COMMENTS
Atovaquone/Proguanil(MALARONE)
Adult tablets contain250 mg atovaquoneand 100 mg proguanilhydrochloride. 1 adulttablet orally, daily
Pediatric tablets (62.5 mgatovaquone/25 mg proguanil HCl).5-8 kg: 1/2 ped tab/day>8-10 kg: 3/4 ped tab/day>10-20 kg: 1 ped tab/day>20-30 kg: 2 ped tab/day>30-40 kg: 3 ped tab/day>40 kg: 1 adult tablet daily
Begin 1-2 days before travel to endemic areas. Take daily and for 7 daysafter leaving such areas. Not recommended for prophylaxis for children <5 kg, pregnantwomen, and women breast-feeding infants weighing <5 kg.
39
![Page 39: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/39.jpg)
40
Contd…
Prophylaxis and treatment of malaria
Fixed dose combination 250 mg atovaquone and 100 mg proguanil
hydrochloride
FDC - Treating drug-resistant P. falciparum malaria Chemoprophylaxis of malaria
NOT USED IN INDIA
![Page 40: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/40.jpg)
Atovaquone(Napthaquione)
Tissue Stage
Blood Stage
Gametocidal
Pf
Pv
Po
Pm
As combination, Chemoprophylaxis of P.f malaria & Therapy of Multidrug resistant malaria
• Inhibits ETC in mitochondria Inhibits electron transport and collapses the mitochondrial membrane
• BA ↑ with fatty meals
• 99% of plasma protein bound
• Elimination t1/2 from plasma of 2-3 days in adults and 1-2 days in children
• Mild- abdominal pain, nausea, vomiting, diarrhea, headache, rash warranting cesation
• Not recommended in children <11 kg, pregnant women, and lactating mothers
![Page 41: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/41.jpg)
Proguanil(Buguanides)
Tissue Stage
Blood Stage
Gametocidal
Pf
Pv
Po
Pm
As combination, Chemoprophylaxis of P.f malaria & Therapy of Multidrug resistant malaria
• Acts on Pre erthrocytic stages but not on Hypnozoites
• Metabolized by CYP2C19 to cycloguanil
• Slow blood schizontocides
• In pregnancy, with folate supplements
• Vomiting, abdominal pain• Cast nephropathy.
• Hematological changes (megaloblastic anemia and pancytopenia) - in severe renal impairment
• Rapid resistence if used as monotherapy
![Page 42: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/42.jpg)
Recent Advances
43
![Page 43: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/43.jpg)
1.NEW COMBINATION THERAPY
More Promising than monotherapy Moe efficacious & retards the resistant strains.
44
![Page 44: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/44.jpg)
![Page 45: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/45.jpg)
Arterolane Trioxalane congener of artmisinine . Rapidly acting high efficacy erythrocytic
schizonticide but duration of action is short. Sensitive against resistant plasmodium species. Each tablet of FDC consists of arterolane (150 mg)
and piperaquine (750 mg) OD for 3 days. Status: Ranbaxy Laboratories Limited has received
the regulatory approval for.. Synriam (arterolane maleate 150 mg +piperaquine
phosphate 750 mg drug) in seven African countries- April 2014.
46
![Page 46: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/46.jpg)
PIPERAQUINE
Synthetic Bisquinoline compound belonging to 4-amioquinoline group .
Piperaquine has a slow and longer schizontocidal activity against erythrocytic stages of both P. vivax andP. falciparum chloroquine-resistant strains.
Activity against chloroquine-resistant strains may be attributed to bulky bisquinoline structure itself, which possibly also contributes to inhibition of chloroquine efflux transporters from the parasite food vacuole
47
![Page 47: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/47.jpg)
PYRONARIDINE
Newer drug derived from mepacrine developed in china.
MOA: Similar to chloroquine. Highly effective erythrocytic schizonticide. Effective against both chloroquine sensitive and
resistant strains. At high doses analgesic and antipyretic action is
also seen. S/E – Mild abd. Pain , Headache, vomiting. Artesunate(200mg) + Pyronaridine (600mg) for 3
days in phase III Clinical trials.(Approved in china).48
![Page 48: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/48.jpg)
2.EXISTING TARGETS- NEW DRUGS
49
![Page 49: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/49.jpg)
CHLORPROGUANIL
Chloro derivative of proguanil. MOA: Similar to proguanil. Combined with Dapsone (Lapdap)
Side effect profile and other features similar to Proguanil.
Withdrawn due to hematologic complications in G-6PD Patients
50
![Page 50: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/50.jpg)
5-FLUOROOROTATE Orotic acid, an intermediate of pyrimidine
biosynthesis. 5-fluoroorotate, a cytotoxic derivative of orotic acid,
may be a potent and selective antimalarial agent. In vitro, 5-fluoroorotate caused 50% inhibition of the
growth of Plasmodium falciparum at a concentration of 6.0 nM. In contrast to 5-fluorouracil.
Chloroquine-susceptible and chloroquine-resistant clones of P. falciparum were equally susceptible to 5-fluoroorotate.
51
![Page 51: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/51.jpg)
Existing targets- New Drugs
52
![Page 52: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/52.jpg)
G-25 Promising lead compound. Phosphatidylcholine synthesis inhibitor. In vivo activity against P. falciparum: P. falciparum
infection in Aotus monkeys was cleared 4 days after treatment with G25 dosages as low as 0.03 mg/kg administered twice daily for 8 days.
The researchers comment that G25 was as effective as quinine and pyrimethamine/sulfadoxine.
Indicate that G25 fulfills essential criteria for the development of a new class of antimalarials.
53
![Page 53: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/53.jpg)
Existing targets- New Drugs
54
![Page 54: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/54.jpg)
TAFENOQUINE
Primaquine analogue with a long elimination–half-life (14–28 days for tafenoquine,versus 4–6 hours for primaquine) .
It has activity against the blood and liver stages of malaria .
In vitro and in vivo animal models have shown that tafenoquine is more potent and less toxic than primaquine
Status: Preclinical.
55
![Page 55: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/55.jpg)
ArtemisoneArms InterventionExperimental: Artemisone/Mefloquine (AmiM3)
Drug: Artemisone/Mefloquine (AmiM3)Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
Active Comparator: Artesunate/Mefloquine (MAS3)
Drug: ArtesunateArtesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
56
Shown promising efficacy for the treatment of uncomplicated falciparum malaria in phase III trials in Thailand and seems to be at least as efficacious as artesunate. No significant toxicity has been reported for artemisone and it is very well tolerated.Status – Phase III.
![Page 56: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/56.jpg)
57
3.New targets- New Drugs
Apicoplast targets:Chloroplast-like organelle
Maintains specific functions including fatty acid, heme & amino acid metabolism
Fosmidomycin & TE3 are such drug acting on apicoplast.
![Page 57: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/57.jpg)
Fosmidomycin MOA: inhibits the 1-desoxy-D-xylulose-5-
phosphate reductoisomerase in the mevalonate-independent pathway of isoprenoid synthesis in apicoplast.
Fosmidomycin was initially developed as an antibacterial drug, but has shown efficacy in combination with clindamycin or azithromycin against P. falciparum malaria.
In combination with clindamycin . Discontinued - Phase-II for Malaria (In children) in
Mozambique due to unfavourable results. (NCT01464138) .
58
![Page 58: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/58.jpg)
TE3 TE3, a prodrug of a bis-ammonium compound Acts on phospholipid metabolism through the
inhibition of de novo phosphatidylcholine synthesis in apicoplast
combined with a putative activity on heme detoxification.
This new class of compounds has shown potent in vivo antimalarial activity in the primate model Aotus
No cross resistance in vitro with known antimalarials.
Status: Preclinical.
59
![Page 59: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/59.jpg)
Ozonide OZ439
• Synthetic peroxide antimalarial drug candidate
• Designed to provide a single-dose oral cure in humans.
• After success in Phase I trials, undergoing Phase IIa trials in malaria patients.
• A fast-acting against all asexual erythrocytic P.falciparum stages comparable to semisynthetic artemisinin derivatives.
• Good efficacy and prolonged blood concentrations.
60
![Page 60: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/60.jpg)
4.Drugs reversing Chloroquine Resistance >> > Experimental. Ca-Channel Blockers: Verapamil Phenothiazines : Desipramine Antihistaminic : Chlorpheniramine Vitamin E : Deficiency may afford protecton Erythocyte specific Ab encapsulated in
liposomes: to circumvent Chloroquine-resistance.
61
![Page 61: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/61.jpg)
62
The rigid tricyclic aromatic acridone core :The side-chain attachment at the central nitrogen atom provides a hydrogen bond acceptor needed for the chemosensitization function, and, together with the side chain at position 6, facilitates accumulation in the digestive vacuole (DV) via acid trapping
5.New chemosensitizing agents
![Page 62: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/62.jpg)
New chemosensitizing agents Tricyclic acridone molecules with a short alkyl
amine chain attached to the central nitrogen atom could make chloroquine-resistant parasites susceptible to the drug again. (Chemo sensitizing action)
This action is attributed to blocking the PfCRT pump protein, meaning that the chloroquine can reach its target.•
This new class of antimalarial drug have dual role it can reverse the malaria parasites resistance to existing drugs and also have antimalarial action.
These are in early Preclinical phase of development.
63
![Page 63: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/63.jpg)
64
1) Glycolysis is another cytosolic pathway of interest Parasites depend on this - energy production
Plasmodial lactate dehydrogenase2) Malaria parasites cannot synthesize purines, rely on
salvage of host purines for nucleic acid synthesis viz Hypoxanthine
Hypoxanthine–guanine phosphoribosyltransferase
3) Proteases of Hb hydrolysis in food vacuole viz 1) Aspartic proteases - Plasmepsins Cysteine proteases - Falcipains Serine proteases
![Page 64: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/64.jpg)
65
7.Antimalarial Vaccine
![Page 65: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/65.jpg)
![Page 66: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/66.jpg)
![Page 67: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/67.jpg)
![Page 68: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/68.jpg)
![Page 69: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/69.jpg)
Altruistic vaccine: it is a transmission blocking vaccine.
![Page 70: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/70.jpg)
71
Circumsporozoite protein The circumsporozoite (CS) protein is the pre-
erythrocytic antigen against which immune responses are most clearly linked to
Protection. Antibodies are primarily directed against the central
conserved repeat region. Most promising CSP candidates include
immunodominant B cell epitopes present in the central repeat (NANP) region and T cell epitopes from the C terminal portion of the molecule.
Numerous vaccine constructs have been developed that are directed against the CS protein.
![Page 71: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/71.jpg)
72
RTS,S/AS02 Vaccine Hybrid construct of the hepatitis B surface antigen
fused with a recombinant antigen derived from part of circum sporozoite protein ––CSP repeat region (R)
T-cell epitopes (T) fused to the hepatitis B surface antigen (S)
Co-expressed with unfused S antigen AS-02:Innovative adjuvant systems that was
critical to the success of this vaccine. Primarily for use in infants and young children in
sub saharan Africa
![Page 72: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/72.jpg)
New Malarial Vaccines Status
Parasite stage
Vaccine Stage of Development
PreErythrocytic Stage
CSP C-ter peptide + Montanide ISA 720 Phase Ib
ICC-1132: Hybrid CSP multiepitope-HBc VLPs
Phase II
RTS,S: Hybrid P. falciparum CSP -HBsAg particles + AS02 adjuvant
APPROVED
DNA vaccines (including MuStDO-5:CSP/LSA-1/ LSA-3/EXP1/TRAP)
Phase I
Live recombinant FPV- or MVA-CSP+ LSA-1 epitope
Phase Ib
Live recombinant MVA-multiepitopestring + TRAP
Phase Ib
![Page 73: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/73.jpg)
The PATH Malaria Vaccine Initiative (MVI) : a global program of the international nonprofit organization PATH. MVI was established in 1999 through a grant from the Bill & Melinda Gates Foundation.
GOAL: To develop an 80% efficacious malaria vaccine by 2025 that would provide protection for at least four years
![Page 74: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/74.jpg)
RESULT Mosquirix :
First FDA Approved vaccine (July 2015). RTS,S type Pre-erythrocytic vaccine. Basically designed for children of Sub Sahara African
Countries. Dose: Three intramuscular injections of 10 μg, 25μg and 50
μg doses of RTS,S/AS02 delivered as fractional (0.1 ml, 0.25 ml) or standard (0.5 ml) volumes of the adjuvanted vaccine on a 0-1- and 3month schedule.
Safety: The most frequently general solicited symptoms related to vaccination were myalgia and fatigue and headache.
75
![Page 75: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/75.jpg)
8.ROLE OF GENOME SEQUENCING
Pattern for Spread of resistance is same globally. Max 4-8 point mutation is seen in within 200 KB of
chromosome 7.Method: Identify the infected individual Blood collection by Medical person Identification of altered gene Multiplication into complete genome
Development of mapping sequence of resistance for that region.
Used in African countries.In India ASSAM is first state to have genomic
database.76
![Page 76: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/76.jpg)
77
![Page 77: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/77.jpg)
78
Acacia farnesiana
Carica papaya leaf extract
Cinnamonium bejolghota
Croton tiglium
![Page 78: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/78.jpg)
Conclusion The emergence and spread of drug resistant malaria
represents a considerable challenge to controlling malaria.
WHO advocates Artemisinin combination therapy for uncomplicated falciparum malaria. Very few new drugs are in pipeline as compared to
existing targets. In such scenario Genetic maping and vaccines may play a
pivotal role in future. It is essential to ensure rational deployment of the few
remaining effective drugs, to maximize their useful therapeutic life.
![Page 79: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/79.jpg)
REFERENCES: Bruton, Chabner BA, Knollman BC: Chapter 49.Chemotherapy Of Malaria.
GOODMAN & GILLMAN’S The pharmacological basis of therapeutics. section VII ModulationChemotherapy of Micribial Diseases; 12th edition. vSan Diego, December 1, 2010.P.1383-18.
Biamonte M a, Wanner J, Le Roch KG. Recent advances in malaria drug discovery. Bioorg Med Chem Lett. Elsevier Ltd; 2013 May 15;23(10):2829–43. El Ahmadieh TY, Aoun SG, Daou MR, El Tecle NE, Rahme RJ, Graham RB, et al. New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery. J Clin Neurosci. Elsevier Ltd; 2013 Oct;20(10):1350–6.
Beteck RM, Smit FJ, Haynes RK, N’Da DD. Recent progress in the development of anti-malarial drugs. Malar J. 2014 Jan;13(1):339.
Patil C, Katare S, Baig M, Doifode S. Fixed dose combination of arterolane and piperaquine: A newer prospect in antimalarial therapy. Ann Med Heal.2015;4(4):466–71.
80
![Page 80: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/80.jpg)
REFERENCES:
Naidoo I, Roper C. Mapping “partially resistant”, “fully resistant”, and “super resistant” malaria. Trends Parasitol. Elsevier Ltd; 2013 Oct;29(10):505–15.
Dunyo S, Sirugo G, Sesay S, Bisseye C, Njie F, Adiamoh M, et al. Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia. PLoS One. 2011 Jan;6(6):e17371.
Hobbs C, Duffy P. Drugs for malaria: something old, something new, something borrowed. F1000 Biol Rep. 2011:November24.(1):65–107.
Hoffman SL, Vekemans J, Richie TL, Duffy PE. The march toward malaria vaccines. Vaccine. Elsevier Ltd; 2015.
Guidelines for Diagnosis and Treatment of Malaria in India. 2014 www.nvbdcp.org.
81
![Page 81: Resiatant malaria final](https://reader033.vdocuments.us/reader033/viewer/2022042513/58ef800a1a28abb26d8b4591/html5/thumbnails/81.jpg)
Thank You